Syndax Pharmaceuticals, Inc. (SNDX)

Syndax Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	135.94	134.93	154.08	295.39	74.36	221.97
Short-Term Investments	301.32	278.76	428.83	282.19	410.04	224.87
Cash & Short-Term Investments	437.26	413.69	582.91	577.58	484.4	446.83
Cash Growth	-3.72%	-29.03%	0.92%	19.24%	8.41%	50.07%
Accounts Receivable	46.87	38	7.6	-	-	-
Other Receivables	32.92	32.3	6.27	1.23	4.06	0.43
Receivables	79.78	70.29	13.87	1.23	4.06	0.43
Inventory	43.83	39.01	2.38	-	-	-
Prepaid Expenses	3.62	3.88	3.29	2	1.22	0.87
Restricted Cash	-	-	-	-	-	0.12
Other Current Assets	2.95	1.22	0.61	0.06	0.12	0.15
Total Current Assets	567.44	528.08	603.06	580.88	489.79	448.4
Property, Plant & Equipment	1.16	1.52	2.02	1.5	1.06	1.26
Long-Term Investments	123.98	-	119.52	29.83	5.47	-
Other Long-Term Assets	0.1	0.1	0.22	0.68	0.92	-
Total Assets	692.67	529.71	724.82	612.88	497.24	449.66

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	3.57	16.58	11.63	9.96	4.35	5.67
Accrued Expenses	114.91	102.34	59.68	38.97	23.67	12.76
Current Portion of Long-Term Debt	-	-	12.12	-	-	-
Current Portion of Leases	0.53	0.47	0.48	1.05	0.44	0.36
Other Current Liabilities	1.96	0.72	19.65	8.12	0.6	1.89
Total Current Liabilities	120.96	120.12	103.55	58.1	29.07	20.68
Long-Term Debt	588.28	343.91	331.57	-	-	19.9
Long-Term Leases	0.61	1.05	1.58	0.59	0.72	0.71
Total Liabilities	709.85	465.08	436.69	58.68	29.79	41.29

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-In Capital	1,633	1,571	1,509	1,456	1,161	952.02
Retained Earnings	-1,648	-1,507	-1,221	-902.4	-693.04	-543.7
Comprehensive Income & Other	-1.67	0.45	0.16	0.22	-0.81	0.05
Total Common Equity	-17.18	64.63	288.12	554.2	467.45	408.37
Shareholders' Equity	-17.18	64.63	288.12	554.2	467.45	408.37
Total Liabilities & Equity	692.67	529.71	724.82	612.88	497.24	449.66

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	589.42	345.43	345.74	1.64	1.16	20.97
Net Cash (Debt)	-152.16	68.25	237.17	575.95	483.24	425.86
Net Cash Growth	-	-71.22%	-58.82%	19.19%	13.47%	53.62%
Net Cash Per Share	-1.72	0.79	2.77	8.18	7.95	7.94
Filing Date Shares Outstanding	90.03	88.2	86.02	84.97	68.44	55.01
Total Common Shares Outstanding	89.99	87.41	85.69	84.83	68.11	54.98
Working Capital	446.47	407.97	499.51	522.78	460.72	427.71
Book Value Per Share	-0.19	0.74	3.36	6.53	6.86	7.43
Tangible Book Value	-17.18	64.63	288.12	554.2	467.45	408.37
Tangible Book Value Per Share	-0.19	0.74	3.36	6.53	6.86	7.43
Machinery	0.48	0.44	0.25	0.25	0.25	0.54
Leasehold Improvements	0.17	0.17	0.17	0.17	0.17	0.17

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Nov 2, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 3, 2026

Data Sources Report a data error